Showing 2681-2690 of 4087 results for "".
Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0709_04-php/22799/How Viable is Pay-for-Performance in Dermatology?
https://practicaldermatology.com/topics/general-topics/PD0509_03-php/22825/Though Pay-for-Performance has affected primary care medicine for years, it has only recently expanded into specialized medicine. Experts discuss its eventual impact on dermatology.Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0509_05-php/22827/Is Topical Therapy for Psoriasis Resurging?
https://practicaldermatology.com/topics/psoriasis/PD0409_03-php/22841/While biologics have changed the way patients and physicians think about psoriasis, topical therapy remains important for a majority of patients.Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0409_05-php/22843/Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0309_06-php/22860/You Want to Start A New Practice: Now What?
https://practicaldermatology.com/topics/general-topics/PD0309_12-php/22866/After making the decision to start a practice, constructing a solid business plan and financial overview is critical.What Do New PhRMA Guidelines Mean for Dermatology?
https://practicaldermatology.com/topics/general-topics/PD0309_04-php/22858/Revisions to the "Code on Interactions" are taking effect, but what do they really mean for the typical clinician?- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f